• What is CMT?
    • About CMT
    • Type1
      • What is CMT1A?
      • What is CMT1B?
      • What is CMT1E?
      • What is HNPP?
    • Type2
      • What is CMT2A?
    • Type4
      • What is SORD?
    • TypeX
      • Understanding CMT1X/CMTX1 and GJB1
    • —-
    • Watch Our Video Series
    • Learn About Treatments in Development
  • Research
    • Research Approach
    • Research Projects We Fund
    • Research Pipeline
    • Gene Therapy
    • Clinical Trials
    • —-
    • Apply for Funding
    • Emerging Researcher Award
  • News & Stories
    • News
    • CMT Stories
  • Take Action
  • About Us
    • Who We Are
    • Board of Directors
    • Research Advisory Council
    • Scientific Advisory Board
    • Research Foundation Staff
    • Events
    • Financials
    • Contact Us
    • Velocity
    • Global CMT Research Convention
  • Donate
A Father Who Defies ‘Impossible’: Joao Cardoso’s Journey with CMT

A Father Who Defies ‘Impossible’: Joao Cardoso’s Journey with CMT

Jun 13, 2025 | Life with CMT

Joao Cardoso, Brittany, France, Living with CMT Joao Cardoso never imagined that he would be riding through the town of Brittany, France, in a wheelchair, while his eight-year-old son, Edgar, pedals his bike alongside him. Because of Joao’s Charcot-Marie-Tooth...
Siemens’ Ann Fairchild Joins CMT Research Foundation Board of Directors

Siemens’ Ann Fairchild Joins CMT Research Foundation Board of Directors

Jun 2, 2025 | Foundation News

CMT Research Foundation is pleased to announce that Ann Fairchild, executive vice president and general counsel of Siemens USA, has joined the Foundation’s Board of Directors.  Fairchild is a seasoned legal executive with more than 25 years of experience at Siemens,...
Applied Therapeutics Presents Findings From Phase 2/3 Clinical Trial of Govorestat in CMT-SORD

Applied Therapeutics Presents Findings From Phase 2/3 Clinical Trial of Govorestat in CMT-SORD

May 20, 2025 | CMT Research Updates, Drug Development

Applied Therapeutics recently presented findings from their INSPIRE Phase 2/3 clinical trial of govorestat (AT-007) for the treatment of Sorbitol Dehydrogenase Deficiency, a subtype of Charcot-Marie-Tooth disease, at the Peripheral Nerve Society’s 2025 Annual Meeting...
CMT Research Foundation Invests in Asha Therapeutics to Test Novel Drug for CMT2A

CMT Research Foundation Invests in Asha Therapeutics to Test Novel Drug for CMT2A

May 20, 2025 | CMT Research Updates, CMTRF Funded Research, Drug Development

CMT Research Foundation has invested in a research project with Asha Therapeutics to investigate the therapeutic potential of inhibiting SARM1 (Sterile alpha and TIR motif-containing protein 1) using their novel drug, ASHA-624, for the treatment of Charcot-Marie-Tooth...
Vanderbilt University Researchers Identify Promising Compounds Targeting PMP22 Protein Expression, Paving the Way for New Treatments for CMT1A, CMT1E and HNPP

Vanderbilt University Researchers Identify Promising Compounds Targeting PMP22 Protein Expression, Paving the Way for New Treatments for CMT1A, CMT1E and HNPP

May 12, 2025 | CMT Research Updates, CMTRF Funded Research

Researchers at Vanderbilt University have made significant progress in the development of small molecules aimed at treating Charcot-Marie-Tooth disease types caused by mutations in the PMP22 gene, which include CMT1A, CMT1E and hereditary neuropathy with liability to...
« Older Entries

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Foundation News
  • Life with CMT
  • Research News

Help us find a cure.

Donate Now
Donate Now

Help us find a cure.

NEWSLETTER SIGNUP

Stay up to date on new CMT research, treatments and clinical trials



Address

4062 Peachtree Road
Suite A209
Atlanta, GA 30319



Phone Number

404.806.7180



EMAIL

[email protected]

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2025 CMT Research Foundation | Privacy Policy

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}